NCT00126633View on ClinicalTrials.gov

Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

September 30, 2006

Study Completion Date

October 31, 2008

Conditions
Pancreatic Cancer
Interventions
BIOLOGICAL

bevacizumab

DRUG

cisplatin

DRUG

gemcitabine hydrochloride

Trial Locations (1)

94115

UCSF Comprehensive Cancer Center, San Francisco

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of California, San Francisco

OTHER

NCT00126633 - Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter